References
- Ingram JT. The approach to psoriasis. BMJ 1953; 12: 591–4
- Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44
- Bohlen P, Grove J, Beya MF, et al. Skin polyamine levels in psoriasis. The effect of dithranol therapy. Eur J Clin Invest 1978; 8: 215–18
- Anderson T F, Waldinger T P, Woorhees JJ. UV-B phototherapy. Arch Dermatol 1984; 120: 1502–7
- Ashton R E, Andre P, Lowe NJ, et al. Anthralin: Historical and current perspectives. J Am Acad Dermatol 1983; 9: 173–92
- Saihan E M, Albano J, Buston JL. The effect of steroid and dithranol therapy on cyclic nucleotides in psoriatic epidermis. Br J Dermatol 1980; 102: 565–9
- Hammer H. Glyceraldehydephosphate dehydrogenase and glucose-6-phosphate dehydrogenase activities in psoriasis and neurodermatitis and the effect of dithranol. J Invest Dermatol 1970; 54: 121–5
- Bridges B A, Greaves M W, Polani PE, et al. Do treatments available for psoriasis carry a genetic or carcinogenic risk. Mutat Res 1981; 86: 279–304
- Marsden J R, Coburn P R, Marks JM, et al. Response to short term application of dithranol in psoriasis. Br J Dermatol 1983; 108: 243
- Ragaz A, Ackerman AB. Evolution, maturation, and regression of lesions of psoriasis. Am J Dermatopathol 1979; 1(3)199–214
- Suurmond D. Histologic changes in treated and untreated psoriatic lesions. Acta Derm Venereol (Stockh) 1965; 131: 357–66
- Wilborn W H, Montes LF. Ultrastructural changes in psoriatic epidermis following anthralin treatment. J Cutan Pathol 1974; 1: 132–50
- Champion RH. Psoriasis. BMJ 1986; 292: 1693–6
- Lowe N J, Breeding J, Wortzman MS. The pharmacological variability of crude coal tar. Br J Dermatol 1982; 107: 475–9
- Obermayer M E, Becker SW. A study of crude coal tar and allied substances. Arch Dermatol Syphilol 1935; 31: 796–810
- Goeckerman WH. The treatment of psoriasis. Northwest Med 1925; 24: 2–9
- Parrish JA. Treatment of psoriasis with long-wave ultraviolet light. Arch Dermatol 1977; 113: 1525–8
- Gupta A K, Anderson TF. Psoralen photochemotherapy. J Am Acad Dermatol 1987; 17: 703–34
- Bowers R E, Dalton D, Fursdon D, et al. The treatment of psoriasis with UVR, dithranol paste, and tar baths. Br J Dermatol 1966; 78: 273–81
- Comaish S, Smith J, Seville RH. Factors affecting the clearance of psoriasis with dithranol (anthralin). Br J Dermatol 1971; 84: 282–9
- Weigland D A, Everett MA. Clearing of resistant psoriasis with anthralin. Arch Dermatol 1967; 96: 554–9
- De Bersaques J. A retrospective study of the inpatient treatment of psoriasis with dithranol. Dermatologica 1987; 175: 64–8
- Durham G, Morgan J. A 7-year follow-up study of ninety patients with psoriasis. Br J Dermatol 1974; 91: 7–11
- Elder J T, Hammerberg C, Cooper KD, et al. Cyclosporin A rapidly inhibits epidermal cytokine expression in psoriasis lesions, but not in cytokine stimulated cultured keratin-ocytes. J Invest Dermatol 1993; 101: 761–6
- Gejman P V, Ram A, Gelernter J, et al. No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. JAMA 1994; 271(3)204–8
- Harland C C, Whitaker R P, Barron JL, et al. Increased urine neopterin levels in psoriasis. Br J Dermatol 1992; 127: 453–7